Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for reduced cardiovascular risk

Preventive Cardiology

Volumn 12, Issue 1, 2009, Pages 43-50

  Liebson, Philip R ^a   Amsterdam, Ezra A ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; VASODILATOR AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; FOLLOW UP; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HEALTH; INCIDENCE; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; RAMIPRIL; RISK FACTORS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 63849189587     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.00010.x     Document Type: Review

References (38)

1. Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol 2005, 42:S50-S56.
2. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-1559.
3. Liebson PR. Clinical Trial Update: ENHANCE and ONTARGET. Prev Cardiol. 2008, 11:179-182.
4. Werner C, Baumhäkel M, Teo KK. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008, 3:418-431. [Epub]
5. Okunishu H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin-II generating enzyme in the vascular wall. J Hypertens. 1984, 2:277-284.
6. Nickenig G, Harrison DG. The AT (1)-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation. 2002, 105:393-396.
7. Wassman S, Nickenig G. Pathophysiological regulation of the AT1-receptor and Implications for vascular disease. J Hypertens. 2006, 24:S15-S21.
8. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001, 345:1689-1697.
9. Yusuf S. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000, 342:145-153.
10. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000, 355:253-259.
11. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003, 362:782-788.
12. Braunwald E, Domanski MJ, Fowler SE. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004, 351:2058-2068. [PEACE trial]
13. Unger T, Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol. 2007, 100:25J-31J.
14. Bahlmann FH, deGroot K, Mueller O. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005, 45:526-529.
15. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007, 115:518-533.
16. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345:861-869.
17. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345:851-860.
18. Schmieder RE, Delles C, Mimran A. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007, 30:1351-1356.
19. Barnett AH, Bain SC, Bouter P. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004, 351:1952-1961.
20. Granger CB, McMurray JJ, Yusuf S. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003, 362A:772-776.
21. Maggioni AP, Anand I, Gottlieb SO. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002, 40:1414-1421.
22. Yusuf S, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003, 362:777-781.
23. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival study ELITE II. Lancet. 2000, 355:1582-1587.
24. Pfeffer MA, McMurray JJ, Velazquez EJ. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003, 349:1893-1906.
25. McMurray JJ, Ostergren J, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003, 362:767-771.
26. Cohn JN, Tognoni G. Valsartan Heart Failoure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001, 345:1667-1675.
27. McKelvie RS, Yusuf S, Pericak D. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation. 1999, 100:1056-1064.
28. McMurray J, Solomon S, Pieper K. The effect of valsartan, captopril, or both on atherosclerotic events after myocardial infarction. J Am Coll Cardiol. 2006, 47:726-733.
29. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet. 2002, 360:752-760.
30. Lee VC, Rhew DC, Dylan M. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Int Med. 2004, 141:693-704.
31. Phillips CO, Kashani A, Ko DK. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Int Med. 2007, 167:1930-1936.
32. Mancia G, Jakobsen A, Heroys J. Cardiac and vascular protection: the potential of ONTARGET. Medscape J Med. 2008, 10.
33. Kurtz TW, Pravenek M. Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004, 22:2253-2261.
34. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest. 2006, 29:957-961.
35. De Rosa G, Ragonesi PD, Mugellini A. Effects of telmisartan compared eprosartan on blood pressure control. Glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12 month study. Hypertens Res. 2004, 27:457-464.
36. McMurray JJV. ACE inhibitors in cardiovascular disease-unbeatable?. N Engl J Med. 2008, 358:1615-1616.
37. Teo K, Yusuf S, Anderson C. ONTARGET/TRANSCEND Investigators. Rationale, design characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination risk patients; the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Randomized Assessment Study in ACE intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004, 148:52-61.
38. Fitchett D. Clinical trial update: focus on the ONTARGET study. Vas Health Risk Manag. 2007, 3:901-908.